Evidence map›Paper›PMID 25282357›Full record

ArticleNature medicine2014

Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice.

Hanlin Tao, Yong Zhang, Xiangang Zeng, Gerald I Shulman, Shengkan Jin

Open access · greenAbstract read
In one paragraph

Article in Nature medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 1 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 1 synthesis or guideline pooled it, 284 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Repurposing niclosamide to mitigate inflammaging: a review of multi-target mechanisms in cellular senescence and age-related decline.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Mild Mitochondrial Uncoupling for True Ectopic Lipid Disposal.International journal of molecular sciences · 2025
    Review
  17. Review
  18. Article
  19. Article
  20. Article

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hanlin TaoDepartment of Pharmacology, Rutgers University-Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.
Yong ZhangDepartment of Pharmacology, Rutgers University-Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.
Xiangang Zeng1] Department of Pharmacology, Rutgers University-Robert Wood Johnson Medical School, Piscataway, New Jersey, USA. [2] Zhejiang Key Laboratory of Applied Enzymology, Yangtze Delta Region Research Institute of Tsinghua University, Jiaxing, Zhejiang, China.
Gerald I Shulman1] Howard Hughes Medical Institute, Chevy Chase, Maryland, USA. [2] Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA. [3] Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, Connecticut, USA.
Shengkan JinDepartment of Pharmacology, Rutgers University-Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.
Johnson University · USHoward Hughes Medical Institute · US

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Shridar Ganesan · 1997 to 2026
$94.5M
Yale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI Richard A Flavell · 1993 to 2026
$44.0M
Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI WAJAHAT Zafar MEHAL · 1986 to 2026
$31.1M
Yale Mouse Metabolic Phenotyping CenterU24DK059635 · NIDDK · YALE UNIVERSITY · PI SHULMAN, GERALD I · 2001 to 2015
$8.9M
Genetic and Cellular Mechanisms of NAFLD and Hepatic Insulin ResistanceR24DK085638 · NIDDK · YALE UNIVERSITY · PI SHULMAN, GERALD I · 2010 to 2014
$6.3M
Mechanisms of Lipid-Induced Hepatic Insulin ResistanceR01DK040936 · NIDDK · YALE UNIVERSITY · PI SHULMAN, GERALD I · 1989 to 2015
$5.1M
Mouse Metabolic Phenotyping Center (MMPC) at UC DavisU24DK092993 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LLOYD, KC KENT · 2011 to 2015
$4.1M
Mouse Metabolic Phenotyping CenterU24DK076174 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI BRUNENGRABER, HENRI · 2011 to 2015
$2.7M
UMass Mouse Metabolic Phenotyping CenterU24DK093000 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KIM, JASON K · 2011 to 2015
$2.1M
The Role of Autophagy in the Age-related Mitochondrial DeteriorationR01AG030081 · NIA · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI JIN, SHENGKAN VICTOR · 2008 to 2011
$1.0M
The Role of Autophagy in TumorigenesisR01CA116088 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI JIN, SHENGKAN VICTOR · 2007 to 2010
$874k
Howard Hughes Medical InstituteNCI NIH HHS P30 CA072720NCI NIH HHS R01 CA116088NCI NIH HHS R01CA116088NIA NIH HHS R01 AG030081NIA NIH HHS R01AG030081NIDDK NIH HHS P30 DK034989NIDDK NIH HHS P30 DK045735NIDDK NIH HHS P30 DK45735NIDDK NIH HHS R01 DK040936NIDDK NIH HHS R24 DK085638NIDDK NIH HHS U24 DK059635NIDDK NIH HHS U24 DK076174NIDDK NIH HHS U24 DK092993NIDDK NIH HHS U24 DK093000
6 · The paper itself

Abstract

Type 2 diabetes (T2D) has reached an epidemic level globally. Most current treatments ameliorate the hyperglycemic symptom of the disease but are not effective in correcting its underlying cause. One important causal factor of T2D is ectopic accumulation of lipids in metabolically sensitive organs such as liver and muscle. Mitochondrial uncoupling, which reduces cellular energy efficiency and increases lipid oxidation, is an appealing therapeutic strategy. The challenge, however, is to discover safe mitochondrial uncouplers for practical use. Niclosamide is an anthelmintic drug approved by the US Food and Drug Administration that uncouples the mitochondria of parasitic worms. Here we show that niclosamide ethanolamine salt (NEN) uncouples mammalian mitochondria at upper nanomolar concentrations. Oral NEN increases energy expenditure and lipid metabolism in mice. It is also efficacious in preventing and treating hepatic steatosis and insulin resistance induced by a high-fat diet. Moreover, it improves glycemic control and delays disease progression in db/db mice. Given the well-documented safety profile of NEN, our study provides a potentially new and practical pharmacological approach for treating T2D.

Indexed as

Administration, OralAnimalsBlood GlucoseCell RespirationDiabetes Mellitus, ExperimentalDiet, High-FatDisease Models, AnimalEnergy MetabolismFastingFatty LiverGlucose Clamp TechniqueHep G2 CellsHumansHyperglycemiaInsulin ResistanceLiverBlood GlucoseNiclosamideUncoupling Agents

Identifiers

PMID25282357
PMCPMC4299950
OpenAlexW1985819704

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.